Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | PLAU | P00749 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | ALPL | P05186 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5046239 | 0.81 | KMT2A (0.35) | HTTKMT2APLAUDYRK1AMEN1 | |
| SCHEMBL31430877 | 0.81 | KMT2A (0.37) | HTTKMT2APLAUDYRK1AMEN1 | |
| SCHEMBL856508 | 0.81 | KMT2A (0.37) | HTTKMT2APLAUDYRK1AMEN1 | |
| SCHEMBL25233643 | 0.79 | ALDH1A1 (0.39) | HTTKMT2APLAUMAPTALPL | |
| SCHEMBL1543624 | 0.79 | PDXK (0.46) | HTTKMT2APLAUMEN1MAPT | |
| SCHEMBL15052641 | 0.79 | CCR5 (0.42) | HTTKMT2APLAUDYRK1A | |
| Hydrochloric Acid SCHEMBL16635240 | 0.78 | CCR5 (0.41) | HTTKMT2APLAUDYRK1A | |
| SCHEMBL13519513 | 0.76 | SIRT2 (0.35) | HTTKMT2APLAUALPL | |
| SCHEMBL2066886 | 0.76 | KMT2A (0.36) | HTTKMT2APLAUMEN1 | |
| SCHEMBL17490830 | 0.75 | HTT (0.54) | HTTKMT2APLAUDYRK1AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2794600-B1 | 2,3-Dihydro-benzo[1,4]oxazine derivatives and related compounds as phosphoinositide-3 kinase (PI3K) inhibitors for the treatment of e.g. rheumatoid arthritis | NOVARTIS AG (CH) | 2017-12-06 | — | — | EP | disclosed |
| US-9763952-B2 | Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives | NOVARTIS AG (CH) | 2017-09-19 | — | — | US | disclosed |
| US-9539260-B2 | Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives | NOVARTIS AG (CH) | 2017-01-10 | — | — | US | disclosed |
| US-20160106753-A1 | Dihydro-Benzo-Oxazine and Dihydro-Pyrido-Oxazine Derivatives | NOVARTIS AG (CH) | 2016-04-21 | — | — | US | disclosed |
| US-20150148377-A1 | Quinoline Derivatives | NOVARTIS AG (CH) | 2015-05-28 | — | — | US | disclosed |
| US-20150148377-A1 | Quinoline Derivatives | NOVARTIS AG (CH) | 2015-05-28 | — | — | US | disclosed |
| US-20150148377-A1 | Quinoline Derivatives | NOVARTIS AG (CH) | 2015-05-28 | — | — | US | disclosed |
| EP-2794594-A1 | QUINOLINE DERIVATIVES | Novartis AG (CH) | 2014-10-29 | — | — | EP | disclosed |
| EP-2794600-A1 | DIHYDRO-BENZO-OXAZINE AND DIHYDRO-PYRIDO-OXAZINE DERIVATIVES | Novartis AG (CH) | 2014-10-29 | — | — | EP | disclosed |
| WO-2013093849-A1 | DIHYDRO-BENZO-OXAZINE AND DIHYDRO-PYRIDO-OXAZINE DERIVATIVES | NOVARTIS AG (CH) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013093850-A1 | QUINOLINE DERIVATIVES | NOVARTIS AG (CH) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013093850-A1 | QUINOLINE DERIVATIVES | NOVARTIS AG (CH) | 2013-06-27 | — | — | WO | disclosed |
| US-20130165436-A1 | Dihydro-Benzo-Oxazine and Dihydro-Pyrido-Oxazine Derivatives | NOVARTIS AG (CH) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165436-A1 | Dihydro-Benzo-Oxazine and Dihydro-Pyrido-Oxazine Derivatives | PDXK, PDK1, DPYD | HTT 1563/4885KMT2A 3812/4885PLAU 1983/4885 |
| US-20150148377-A1 | Quinoline Derivatives | RECQL, NQO2, PIK3R3 | HTT 504/4885KMT2A 2752/4885PLAU 3223/4885 |
| US-20160106753-A1 | Dihydro-Benzo-Oxazine and Dihydro-Pyrido-Oxazine Derivatives | PDXK, PDK1, DPYD | HTT 1563/4885KMT2A 3812/4885PLAU 1983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.